RxDoctor Payments Data

Cassandra Crow

Psychiatric/Mental Health · Weatherford, TXNPI 1285399147

Payments from drug & device makers

$2,811in general payments, 2019–2025

Across 186 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$729
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$498
  • Neurocrine Biosciences, Inc.$439
  • Alkermes, Inc.$317
  • Lundbeck LLC$196
  • E.r. Squibb & Sons, L.L.C.$186
  • plus $447 from 7 others

What the payments were for

  • Food & beverage$2,811100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,811 in reported general payments places this provider in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$11,690
Medicare patients
31
Services billed
157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UzedyRisperidone26$140,262
Invega SustennaPaliperidone Palmitate26$92,342
Abilify MaintenaAripiprazole14$39,495
VraylarCariprazine Hcl19$29,354
VivitrolNaltrexone Microspheres12$20,234
TrintellixVortioxetine Hydrobromide33$16,114
Lurasidone Hcl21$6,754
Clozapine22$5,874
Trazodone Hcl237$3,515
Duloxetine Hcl192$2,686
Buspirone Hcl166$2,232
Chlorpromazine Hcl27$2,026
Aripiprazole60$2,026
Quetiapine Fumarate121$1,510
Haloperidol Decanoate19$1,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Uzedy$729$140,26226 claims
Johnson & JohnsonInvega Sustenna$113$92,34226 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$137$39,49514 claims
AbbVieVraylar$70$29,35419 claims
Alkermes, Inc.Vivitrol$317$20,23412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Weatherford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →